skip to Main Content

Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices

Some products are too cheap, generic drug companies do not invest in them because they do not make enough money out of them. Others seem astronomically expensive, and are said to include the costs of all research, successes and failures alike. Panellists at a recent Swiss-organised expert event in Bern concurred that something must done about pricing, and explored some surprising ways to do it.
Go to Source
Author: Catherine Saez

Back To Top